These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30661956)

  • 1. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?
    Doshi P; Sieluk J; Hung A
    J Am Pharm Assoc (2003); 2019; 59(2):195-201. PubMed ID: 30661956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Information regarding adverse drug effects and treatment indications ("package inserts") exemplified by cervistatin (Lipobay)].
    Braun RN; Halhuber MJ; Hitzenberger G
    Wien Med Wochenschr; 2003; 153(3-4):80-2. PubMed ID: 12658968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient information leaflets and package inserts of ibuprofen provided in the UK and Thailand: a comparative assessment.
    Nualdaisri P; Corlett SA; Krska J
    Int J Pharm Pract; 2024 May; 32(3):208-215. PubMed ID: 38442896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consumer medication information in the United States, Europe, and Australia: a comparative evaluation.
    Raynor DK; Svarstad B; Knapp P; Aslani P; Rogers MB; Koo M; Krass I; Silcock J
    J Am Pharm Assoc (2003); 2007; 47(6):717-24. PubMed ID: 18032134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton Pump Inhibitors and Risk of Rhabdomyolysis.
    Duncan SJ; Howden CW
    Drug Saf; 2017 Jan; 40(1):61-64. PubMed ID: 27838824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient information leaflets--helpful guidance or a source of confusion?
    Bjerrum L; Foged A
    Pharmacoepidemiol Drug Saf; 2003; 12(1):55-9. PubMed ID: 12616848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADHD medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling.
    Sieluk J; Palasik B; dosReis S; Doshi P
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):274-284. PubMed ID: 28083936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm.
    Finks SW; Campbell JD
    Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding adverse drug reactions in package leaflets - an exploratory survey among health care professionals.
    Mühlbauer V; Mühlhauser I
    BMC Health Serv Res; 2015 Nov; 15():505. PubMed ID: 26554666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA.
    Hirata-Koizumi M; Saito M; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2007 Apr; 32(2):177-85. PubMed ID: 17381668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Readability assessment of package leaflets of biosimilars.
    Piñero-López MÁ; Figueiredo-Escribá C; Modamio P; Lastra CF; Mariño EL
    BMJ Open; 2019 Jan; 9(1):e024837. PubMed ID: 30659042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Package leaflets of the most consumed medicines in Portugal: safety and regulatory compliance issues. A descriptive study.
    Pires C; Vigário M; Cavaco A
    Sao Paulo Med J; 2015; 133(2):91-100. PubMed ID: 25337666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The controversies of statin therapy: weighing the evidence.
    Jukema JW; Cannon CP; de Craen AJ; Westendorp RG; Trompet S
    J Am Coll Cardiol; 2012 Sep; 60(10):875-81. PubMed ID: 22902202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of outpatients' use and needs of patient medicine information leaflets in Thailand.
    Pongpunna S; Pratipanawatr T; Jarernsiripornkul N
    Int J Clin Pharm; 2019 Feb; 41(1):141-150. PubMed ID: 30446897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current oral contraceptive use instructions: an analysis of patient package inserts.
    Williams-Deane M; Potter LS
    Fam Plann Perspect; 1992; 24(3):111-5. PubMed ID: 1628713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.